Expert Review Of ImClone Protocol Concludes C225 Approval Unlikely.
Retrospective Data Clean-Up Can’t Help C225 Phase II Trial; Protocol Far Too “Fuzzy”.
ImClone Protocol Generates More Questions Than Answers.
Phase III Trial Would Give Clearer Picture Of C225 Role.
Thomas Jordan To Help ASCO Enhance International Relations, Retires From BMS.
Levine Leaves Presidency Of Rockefeller University.
Trending Stories
- In the epicenter of the measles outbreak, “love thy neighbor” does not extend to vaccination rates
A dispatch from Lancaster County - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - As Iowa goes blue, incoming Gov. Rob Sand and Sen. Josh Turek offer plans to address the state’s “cancer crisis”
- Anthony El-Khoueiry named director of USC Norris
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - Rachna Shroff, accomplished GI oncologist and “tireless mentor,” dies at 47
Her endowed award will live on









